Obesity; Drug Clinical Trial
Official title:
Perioperative Cefuroxime in Obese Patients: Dosage According to the BMI
This study evaluates the dosage of perioperative cefuroxime for obese patients. Dosage was increased if the BMI was over 30kg/m*m and as well over 50kg/m*m. Drug levels were measured in blood and tissue.
Cefuroxime is an often used antibiotic for surgery antibiotic prophylaxis to avoid surgical
wound infection. In this study the dosage of cefuroxime was adjusted to the BMI:
less than 30kg/m*m: 1,5g 31-50kg/m*m: 3,0g more than 50kg/m*m: 4,5g
Cefuroxime was applicated 30 to 60 minutes before the begin of surgery. Drug Levels in blood
and fat tissue were measured at skin cut (30-60 minutes after application of Cefuroxime), 45
minutes after skin cut (75-105 minutes after minutes after application of Cefuroxime) and at
the end of surgery (up to 150 minutes after application of Cefuroxime) .
The hypothesis of this study is that adequate drug levels are reached in all groups.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05162001 -
Body Weight Response With Disulfiram in Humans
|
Early Phase 1 | |
| Recruiting |
NCT05176626 -
Long-term Effectiveness of the Antiobesity Medication Phentermine
|
Phase 4 | |
| Not yet recruiting |
NCT06431308 -
Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events
|
N/A | |
| Completed |
NCT04730375 -
Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients
|
Phase 2 | |
| Recruiting |
NCT03593668 -
Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control
|
Phase 4 | |
| Recruiting |
NCT05087342 -
Latino Semaglutide Study
|
Phase 3 | |
| Recruiting |
NCT06390501 -
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
|
N/A |